ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
60,682.25
0.61%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Soleno Therapeutics Inc (SLNO)

  7. Soleno Therapeutics Inc (SLNO) News

Soleno Therapeutics (SLNO)

Soleno Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SLNO
DateTimeSourceHeadlineSymbolCompany
28/06/202413:00GlobeNewswire Inc.Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi SyndromeNASDAQ:SLNOSoleno Therapeutics Inc
24/06/202422:18GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
11/06/202401:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
11/06/202401:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
11/06/202401:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
06/06/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
04/06/202413:00GlobeNewswire Inc.Soleno Therapeutics Set to Join Russell 3000® IndexNASDAQ:SLNOSoleno Therapeutics Inc
22/05/202421:05GlobeNewswire Inc.Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024NASDAQ:SLNOSoleno Therapeutics Inc
22/05/202413:00GlobeNewswire Inc.Soleno Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SLNOSoleno Therapeutics Inc
15/05/202413:00GlobeNewswire Inc.Soleno Therapeutics Stands with the Prader-Willi Syndrome CommunityNASDAQ:SLNOSoleno Therapeutics Inc
09/05/202421:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLNOSoleno Therapeutics Inc
09/05/202421:05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
07/05/202422:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
06/05/202421:58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLNOSoleno Therapeutics Inc
03/05/202403:32GlobeNewswire Inc.Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
02/05/202421:01GlobeNewswire Inc.Soleno Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
30/04/202413:00GlobeNewswire Inc.Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeNASDAQ:SLNOSoleno Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)NASDAQ:SLNOSoleno Therapeutics Inc
19/04/202421:05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
08/03/202421:05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
07/03/202411:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
06/03/202421:05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
22/02/202413:00GlobeNewswire Inc.Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:SLNOSoleno Therapeutics Inc
31/01/202421:19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNOSoleno Therapeutics Inc
30/01/202421:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202422:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202422:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202421:05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
24/01/202413:00GlobeNewswire Inc.Soleno Therapeutics Strengthens Leadership Team with Key AppointmentsNASDAQ:SLNOSoleno Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SLNO

Your Recent History

LSE
UKOG
Uk Oil & Gas
LSE
PSN
Persimmon
LSE
NARF
Narf Industries
LSE
ATM
Andrada Mining
LSE
THG
Thg
LSE
HE1
Helium One Global
LSE
PFC
Petrofac
LSE
MILA
Mila Resources
LSE
TRP
Tower Resources
LSE
MATD
Petro Matad
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved